Aβ清除蛋白基因多态性与帕金森病痴呆
该研究纳入456例帕金森病患者(其中103例痴呆),探讨APOE、CST和MME基因变异与脑脊液Aβ1-42水平及痴呆起病的关系,发现APOE和CST风险变异与较低脑脊液Aβ1-42水平相关,CST两个风险等位基因患者从帕金森病起病到痴呆起病的时间间隔趋于更短。
要点
- APOE和CST风险变异与帕金森病患者较低脑脊液Aβ1-42水平相关。
- CST两个风险等位基因患者从帕金森病起病到痴呆起病间隔趋于更短。
- Aβ清除相关基因变异可能参与帕金森病痴呆的发病机制。
核心结论
- 与Aβ清除相关的基因变异参与帕金森病痴呆的发病机制,并可能影响痴呆起病时间。
研究设计与样本
- 横断面研究,纳入456例帕金森病患者,其中103例痴呆,分析APOE、CST和MME基因单核苷酸多态性与人口学变量、临床表型及脑脊液Aβ1-42水平的关系。
主要发现
- APOE和CST基因风险变异与较低脑脊液Aβ1-42水平相关。
- CST两个风险等位基因患者从帕金森病起病到痴呆起病的时间间隔趋于更短。
临床怎么用
- 对帕金森病患者可关注APOE和CST基因变异,辅助评估痴呆风险及起病时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether genetic variants in β-amyloid (Aβ) clearance proteins are associated with CSF levels of Aβ1-42 on a biological level and the onset of dementia on a clinical level in Parkinson disease (PD). METHODS: We analyzed genetic variants known to be involved in Aβ clearance in a PD group comprising 456 patients, 103 of them with dementia. Single nucleotide polymorphisms in the genes APOE, cystatin C (CST), and membrane metalloendopeptidase (MME) were evaluated in relation to demographic variables, clinical phenotypes, and CSF Aβ1-42 levels using a cross-sectional approach. RESULTS: Risk variants in the genes APOE and CST were associated with lower CSF Aβ1-42 levels. Clinically, patients with 2 risk alleles in CST tended to show a shorter interval from age at onset of PD to age at onset of dementia. CONCLUSIONS: This study suggests that genetic variants associated with Aβ clearance are involved in the pathogenesis of dementia in PD and possibly influence the onset of dementia.
引用
- Brockmann K, Lerche S, Dilger SS, et al. SNPs in Aβ clearance proteins: Lower CSF Aβ1-42 levels and earlier onset of dementia in PD. Neurology. 2017. PMID: 29117956. doi:10.1212/WNL.0000000000004705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。